Non-Hodgkin Lymphoma

Living a post-cancer lifestyle means including your medical history on a health declaration form and learning to deal with the consequences.

Injectable forms of medication may benefit patients with blood cancers.

Targeted therapies, immunotherapies and combinations add new weapons to fight against non-Hodgkin lymphoma.

A study published in Blood demonstrated the significant disparities found between insurance status and survival outcomes in patients of all ages with follicular lymphoma.
 

The FDA has approved Imbruvica (ibrutinib) for use in combination with Rituxan (rituximab) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.
 

In an interview with CURE, Young explained the importance of whole-person care that included aspects such as yoga and nutrition.

Dewayne Johnson, a patient with cancer who claimed that Monsanto’s Roundup product was at the root of his non-Hodgkin lymphoma diagnosis in 2014, was awarded $289 million by a jury, as reported by the Associated Press.

A new treatment has been approved to treat two rare forms of non-Hodgkin lymphoma. 

With an incidence rate of about three cases per million people a year in the United States, Waldenstrom macroglobulinemia is a rare malignancy, and, therefore, has no widely used screening tools. Diagnosing the disease early and, most important, accurately is the art of medicine that remains to be perfected.

Sometimes, you're ill prepared for a scan that might change the course of your life.